Strain information  NBRP Rat No: 0668  Strain name: F344-Sv2am1Kyo  Commmon Name: Rat Genome Database Principal Investigator:  Tadao Serikawa  Graduate School of Medicine, Kyoto University       Yoshidakonoe-cho, Sakyo-ku    606-8501 Kyoto     JAPAN Tel: 075-753-4360    Fax: 075-753-4409 Email: serikawa@anim.med.kyoto-u.ac.jp Preservation Status:   Embryo        Sperm       Living Animals Coat Color  albino (c) Inbred Generations   Usage Restrictions  The recipient of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. For a commercial use of this resource, a new contract must be concluded between the depositor and the recipient. Genetic Status   Inbred  Segregating   Congenic   Consomic   Recombinant   Coisogenic   Spont. Mutant  Transgene  Ind. Mutant  Category Other  Comercial Availability Research Category   Diabetes Obesity  Neurobiology  Ophthalmology   Dentistry  Cardio Hypertension  Cancer  Metabolism  Otorhinology  Immunology  Infectious  Osteosis   Internal Organ  Dermatology   Reproduction   Development  Behavior  Hematology  Urology   Pharmacology  Research Area Others   Control Strain  Marker Strain Gene Affected Sv2a : synaptic vesicle glycoprotein 2a Origin Established by ENU mutagenesis (gene-driven). This strain has misssense mutation （L174Q）in Sv2a gene. Strain characteristics Sv2aL174Q（F344-Sv2am1Kyo） is a novel rat model carrying the missense mutation (L174Q) in the Sv2a gene encoding the synaptic vesicle glycoprotein 2A. Sv2aL174Q rats show normal appearance and grow well, however, they are sensitive to seizure induction by pentylenetetrazole (PTZ, GABAA antagonist). Sv2aL174Q rats are also very susceptible to the kindling development induced by repeated treatment with PTZ or electrical stimulation of the amygdala. Neurochemical studies reveal that depolarization-evoked synaptic GABA release is impaired in the hippocampus and amygdala of Sv2aL174Q rats. Breeding Conditions Good breeding performance Genotyping References Ohno Y, Tokudome K Therapeutic role of synaptic vesicle glycoprotein 2A (SV2A) in modulating epileptogenesis. CNS Neurol. Disord. Drug Targets, 16:463-471, 2017 Tokudome K, Okumura T, Terada R, Shimizu S, Kunisawa N, Mashimo T, Serikawa T, Sasa M, Ohno Y. A Missense Mutation of the Gene Encoding Synaptic Vesicle Glycoprotein 2A (SV2A) Confers Seizure Susceptibility by Disrupting Amygdalar Synaptic GABA Release. Front Pharmacol. 2016 Jul 14;7:210. Tokudome K, Okumura T, Shimizu S, Mashimo T, Takizawa A, Serikawa T, Terada R, Ishihara S, Kunisawa N, Sasa M, Ohno Y. Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission. Sci Rep. 2016 Jun 6;6:27420. Additional strain information